2.

60例埃克替尼治疗晚期复治NSCLC患者疗效及PFS分析

Analysis of efficacy and PFS for 60 patients with recurrent advanced NSCLC treated with Icotinib hydrochloride

Variable		ORR (%)	P	DCR (%)	P	PFS (mo)	Range (mo)	P
ORR: objective response rate; DCR: disease control rate; PFS: progression free survival.
Gender	Male	26.9	0.014	73.1	0.241	3.5	1.0-18.8	0.013
	Female	58.8		85.3		10.8	1.0-23.5
Age	< 65 yr	40.5	0.282	76.2	0.260	5.3	1.0-23.5	0.769
	≥65 yr	55.6		88.9		7.1	1.0-13.3
PS score	0-1	50.0	0.373	85.3	0.241	5.3	1.0-23.5	0.745
	≥2	38.5		73.1		7.3	1.0-15.3
Smoke	Yes	34.6	0.157	80.8	0.896	5.3	1.0-18.8	0.410
	No	52.9		79.4		7.1	1.0-23.5
Pathological type	Adeno	46.3	0.545	79.6	0.830	7.3	1.0-23.5	0.722
	Squamous	33.3		83.3		3.0	1.4-18.8
Time of treatment	2nd-line	55.6	0.020	88.9	0.024	7.5	1.0-18.8	0.297
	> 2nd-line	26.1		65.2		3.5	1.0-23.5
EGFR mutation status	Mut (+)	65.2	0.006	100.0	＜0.001	10.8	2.3-23.5	0.002
	Wild-type	11.1		44.4		1.4	1.0-9.8
	Unknown	39.3		75.0		7.3	1.0-18.8